Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced that it has enrolled two-thirds of the total patients needed for its Phase 2b clinical trial to study the safety and efficacy of Serdaxin to treat major depressive disorder (MDD). The company began enrollment in January 2011 and plans to enroll a total of 300 patients. The trial is being conducted at 40 sites in the United States.
“Serdaxin’s Phase 2b clinical trial enrollment is on schedule, and we are on track to report preliminary results by the end of this year,” said Rick Soni, President of Rexahn.
The Serdaxin Phase 2b clinical trial is designed as a randomized, double blind, placebo-controlled study with three treatment arms. The primary endpoint is the change from baseline on the Montgomery-Asberg Depression Rating Scale.
Date: May 5, 2011
Source: Rexahn Pharmaceuticals, Inc.
